Janna Morawitz
Overview
Explore the profile of Janna Morawitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
131
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jannusch K, Umutlu L, Kirchner J, Bruckmann N, Morawitz J, Herrmann K, et al.
J Nucl Med
. 2024 Oct;
65(12):1855-1861.
PMID: 39389629
Our rationale was to investigate whether F-FDG PET/MRI in addition to (guideline-recommended) conventional staging leads to changes in therapeutic management in patients with newly diagnosed breast cancer and compare the...
2.
Jannusch K, Dietzel F, Bruckmann N, Morawitz J, Boschheidgen M, Minko P, et al.
Eur J Nucl Med Mol Imaging
. 2023 Dec;
51(5):1451-1461.
PMID: 38133687
Purpose: To evaluate if a machine learning prediction model based on clinical and easily assessable imaging features derived from baseline breast [F]FDG-PET/MRI staging can predict pathologic complete response (pCR) in...
3.
Jannusch K, Bruckmann N, Morawitz J, Boschheidgen M, Quick H, Herrmann K, et al.
Eur Radiol
. 2023 Dec;
34(7):4789-4800.
PMID: 38038758
Objectives: To investigate the specific strengths of MRI and PET components in Ga-PSMA-11 PET/MRI for staging of patients with biochemically recurrent prostate cancer (PCa). Methods: Patients with biochemical recurrence of...
4.
Milosevic A, Styczen H, Haubold J, Kessler L, Grueneisen J, Li Y, et al.
Nucl Med Commun
. 2023 Oct;
44(12):1106-1113.
PMID: 37823259
Purpose: To evaluate a correlation between an MRI-specific marker for cellular density [apparent diffusion coefficient (ADC)] and the expression of Somatostatin Receptors (SSTR) in patients with meningioma of the skull...
5.
Mohrmann S, Kolberg L, Jager B, Hoffmann J, Nestle-Kramling C, Zwiefel K, et al.
Eur J Surg Oncol
. 2023 Sep;
49(11):107031.
PMID: 37683424
Purpose: Residual glandular tissue (RGT) after risk reducing mastectomy (RRME) is associated with a risk of developing breast cancer for women with a familial predisposition. We aim to examine various...
6.
Morawitz J, Bruckmann N, Jannusch K, Dietzel F, Milosevic A, Bittner A, et al.
Cancers (Basel)
. 2023 Jul;
15(14).
PMID: 37509307
This study compares the diagnostic potential of conventional staging (computed tomography (CT), axillary sonography and bone scintigraphy), whole-body magnetic resonance imaging (MRI) and whole-body F-fluorodeoxyglucose positron emission tomography (F-FDG PET/)MRI...
7.
Jannusch K, Morawitz J, Schweiger B, Weiss D, Schimmoller L, Minko P, et al.
Eur Radiol
. 2023 Jun;
33(11):8366-8375.
PMID: 37338559
Objectives: Evaluate the influence of an MRI contrast agent application on primary and follow-up staging in pediatric patients with newly diagnosed lymphoma using [F]FDG PET/MRI to avoid adverse effects and...
8.
Morawitz J, Bruckmann N, Jannusch K, Kirchner J, Antoch G, Loosen S, et al.
Cancers (Basel)
. 2023 May;
15(8).
PMID: 37190295
Locoregional therapy options for CCA are used, in particular, for non-resectable tumors and aim to reduce tumor viability or delay tumor growth and ultimately prolong overall survival. In addition to...
9.
Jannusch K, Lindemann M, Bruckmann N, Morawitz J, Dietzel F, Pomykala K, et al.
Eur Radiol
. 2023 Apr;
33(9):6179-6188.
PMID: 37045980
Objectives: To investigate the diagnostic feasibility of a shortened breast PET/MRI protocol in breast cancer patients. Methods: Altogether 90 women with newly diagnosed T1 (T1) and T2 (T2) breast cancer...
10.
Jannusch K, Bittner A, Bruckmann N, Morawitz J, Stieglitz C, Dietzel F, et al.
Cancers (Basel)
. 2023 Mar;
15(6).
PMID: 36980537
Purpose: Evaluate the diagnostic potential of [F]FDG-PET/MRI data compared with invasive acquired biomarkers in newly diagnosed early breast cancer (BC). Methods: Altogether 169 women with newly diagnosed BC were included....